Budipine

Budipine
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N04BX03 (WHO) ;
Identifiers
	IUPAC name 1-tert-butyl-4,4-diphenylpiperidine;
CAS Number	57982-78-2 ;
PubChem CID	68778;
ChemSpider	62021 ;
UNII	L9026OPI2Z;
KEGG	D07306 ;
ChEMBL	ChEMBL334491 ;
CompTox Dashboard (EPA)	DTXSID20206709 ;
ECHA InfoCard	100.055.494
Chemical and physical data
Formula	C21H27N
Molar mass	293.454 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3;
	InChI InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 ; Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N ;
	(verify)

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.

While its exact mechanism of action is not well characterized, it is believed to be an NMDA receptor antagonist, but also promoting the synthesis of dopamine.

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.

It is an hERG blocker and can produce long QT syndrome as a side effect.

Analogues include prodipine and medipine.